Date published: 2025-12-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

Siglec-6 Inhibitors

Siglec-6 inhibitors as a chemical class are characterized by their ability to modulate the activity of the Siglec-6 protein, which is a sialic acid-binding immunoglobulin-type lectin. This protein typically recognizes sialylated carbohydrates and can transduce signals that influence a variety of cellular processes. The inhibitors listed above are not exclusively selective for Siglec-6 but can impact the function of this protein indirectly through interference with related pathways or cellular mechanisms. These compounds can exert their effects by altering the phosphorylation status of proteins downstream of Siglec-6, disrupting the carbohydrate recognition and binding functions of Siglec-6, or affecting other molecular signalling events and cellular conditions that are necessary for the optimal function of Siglec-6.

The inhibition of Siglec-6 can occur through various mechanisms, such as the direct competition for ligand binding, alteration of the cellular localization and distribution of the protein, or interference with the downstream signaling pathways. Chemicals such as tyrosine kinase inhibitors can affect the phosphorylation events that are critical for Siglec-6 signaling. On the other hand, fucose analogs and sialic acid derivatives can directly compete with the binding of natural ligands to the carbohydrate recognition domain of Siglec-6, resulting in altered signaling. Other inhibitors can influence the protein's activity by modulating intracellular conditions, such as calcium levels, cAMP levels, and the integrity of the cytoskeleton, which are all important for the proper functioning of Siglec-6. Additionally, macroscopic cellular responses, including action potentials and lysosomal functions, can also impact the signaling abilities of Siglec-6.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$25.00
$117.00
$209.00
27
(1)

A tyrosine kinase inhibitor that can interfere with the intracellular signaling cascades, possibly affecting the Siglec-6-associated pathways.

2-Deoxy-D-glucose

154-17-6sc-202010
sc-202010A
1 g
5 g
$65.00
$210.00
26
(2)

A fucose analog that can competitively inhibit the binding of fucose-containing ligands to Siglec-6, thereby modulating its function.

N-Acetylneuraminic acid

131-48-6sc-281055A
sc-281055
sc-281055D
sc-281055B
sc-281055C
1 g
5 g
25 g
100 g
250 g
$82.00
$153.00
$320.00
$572.00
$1336.00
(1)

A sialic acid derivative that can compete with natural sialic acid ligands for Siglec-6 binding, modifying its activity.

Cytochalasin D

22144-77-0sc-201442
sc-201442A
1 mg
5 mg
$145.00
$442.00
64
(4)

An actin polymerization inhibitor that can disrupt cytoskeletal arrangements, potentially affecting Siglec-6's cellular distribution and signaling.

Verapamil

52-53-9sc-507373
1 g
$367.00
(0)

A calcium channel blocker that can alter intracellular Ca2+ levels, influencing Siglec-6 signaling pathways.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

A PI3K inhibitor that can affect the PI3K/Akt pathway, which can intersect with and modulate Siglec-6 activity.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$63.00
$241.00
136
(2)

An inhibitor of MEK, a part of the MAPK pathway, that can alter the functional outcomes of Siglec-6 engagement.

Forskolin

66575-29-9sc-3562
sc-3562A
sc-3562B
sc-3562C
sc-3562D
5 mg
50 mg
1 g
2 g
5 g
$76.00
$150.00
$725.00
$1385.00
$2050.00
73
(3)

An adenylyl cyclase activator that increases cAMP levels, potentially affecting Siglec-6-associated cellular signaling.

BAY 11-7082

19542-67-7sc-200615B
sc-200615
sc-200615A
5 mg
10 mg
50 mg
$61.00
$83.00
$349.00
155
(1)

An NF-κB pathway inhibitor that can modulate the transcriptional activity of genes, possibly affecting Siglec-6 signaling.

Propranolol

525-66-6sc-507425
100 mg
$180.00
(0)

A non-selective beta-adrenergic receptor blocker that can influence GPCR signaling, which can affect pathways that Siglec-6 is involved in.